Insider Selling: Illumina (NASDAQ:ILMN) SVP Sells $127,307.97 in Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Patricia Leckman sold 783 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Price Performance

Shares of Illumina stock traded up $1.99 during trading hours on Tuesday, reaching $160.03. 1,453,928 shares of the company’s stock were exchanged, compared to its average volume of 1,883,252. The business has a fifty day moving average of $138.43 and a two-hundred day moving average of $133.92. The company has a market capitalization of $24.21 billion, a P/E ratio of 29.10, a price-to-earnings-growth ratio of 3.04 and a beta of 1.50. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 1 year low of $85.00 and a 1 year high of $177.22.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the business posted $0.97 earnings per share. Illumina’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Institutional Trading of Illumina

Several institutional investors have recently made changes to their positions in ILMN. Empowered Funds LLC raised its position in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new stake in Illumina in the 2nd quarter valued at approximately $621,000. CW Advisors LLC acquired a new stake in Illumina in the 2nd quarter valued at approximately $275,000. Marshall Wace LLP increased its holdings in Illumina by 49.0% in the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC increased its holdings in Illumina by 30.9% in the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after purchasing an additional 1,748 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Citigroup lifted their price objective on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Guggenheim upped their target price on Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a report on Monday, June 1st. Barclays raised their target price on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Piper Sandler reduced their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Finally, Evercore reissued an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $138.38.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.